Skip to main content

Table 3 Summary of GLY PK parameters by treatment (PK population)

From: Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Parameter statistic

GLY/eFlow

50 μg

(N = 29)

GLY/eFlow

50 μg + Charcoal

(N = 29)

GLY/DPI

63 μg

(N = 28)

GLY/DPI

63 μg + Charcoal

(N = 26)

IV Infusion

50 μg

(N = 27)

Cmax (pg/mL)

 N

29

29

28

26

27

 Mean (SD)

61.46 (39.42)

57.51 (36.32)

199.88 (121.51)

158.96 (62.89)

5287.15 (4131.42)

 CV%

64.14

63.16

60.8

39.57

78.14

tmax (h)

 N

29

29

28

26

27

 Median

0.32

0.25

0.25

0.25

0.10

t½ (h)

 N

13

10

20

20

21

 Median

4.66

5.08

12.99

14.20

4.69

AUC0–24 (h*pg/mL)

 N

29

29

28

26

27

 Mean (SD)

273.47 (442.44)

208.20 (152.78)

581.25 (321.56)

467.56 (187.48)

3314.09 (4220.99)

 CV%

161.787

73.378

55.323

40.098

127.365

AUC0–48 (h*pg/mL)

 N

29

29

28

26

27

 Mean (SD)

314.90 (567.83)

255.48 (223.90)

666.06 (393.78)

546.85 (249.64)

3375.13 (4296.44)

 CV%

180.32

87.64

59.12

45.65

127.30

AUC0-∞ (h*pg/mL)

 N

8

6

15

10

21

 Mean (SD)

292.94 (237.34)

179.56 (75.64)

758.96 (510.22)

654.96 (347.57)

4009.65 (4722.47)

 CV%

81.02

42.12

67.23

53.07

117.78

CL/F (L/h)

 N

8

6

15

10

N/A

 Mean (SD)

255.12 (147.863)

316.99 (117.644)

127.82 (78.670)

131.13 (95.031)

N/A

 CV%

57.957

37.113

61.546

72.473

N/A

Vz/F (L)

 n

8

6

15

10

N/A

 Mean (SD)

1316.34 (395.42)

1690.06 (286.28)

1338.96 (317.19)

1747.07 (385.31)

N/A

 CV%

30.04

16.94

23.69

22.05

N/A

CL (L/h)

 n

N/A

N/A

N/A

N/A

21

 Mean (SD)

N/A

N/A

N/A

N/A

28.13 (24.97)

 CV%

N/A

N/A

N/A

N/A

88.78

Vz (L)

 n

N/A

N/A

N/A

N/A

21

 Mean (SD)

N/A

N/A

N/A

N/A

156.02 (111.98)

 CV%

N/A

N/A

N/A

N/A

71.77

Vss (L)

 n

N/A

N/A

N/A

N/A

21

 Mean (SD)

N/A

N/A

N/A

N/A

51.02 (32.57)

 CV%

N/A

N/A

N/A

N/A

66.26

  1. AUC area under the plasma concentration-time curve, CL clearance, CL/F apparent clearance, Cmax maximum plasma concentration, CV coefficient of variation, DPI dry powder inhaler, GLY glycopyrronium bromide, N/A not applicable, SD standard deviation, tmax time to peak plasma concentration, t1/2 terminal half-life, Vss volume of distribution at steady state, Vz volume of distribution during the elimination phase, Vz/F apparent volume of distribution after extravascular dose administration
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us